2509.HK
QYUNS-B
HK$16.86
+2.18%
2026-05-29
About QYUNS-B
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand. In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD); and QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohn's disease. The company also develops QX027N, an anti-TSLPxIL-13 bispecific antibody that targets AD and asthma indications; QX030N, a IL-23p19/TL1A clinical stage long-acting bispecific antibody for the treatment of inflammatory bowel diseases; QX031N, a clinical stage TSLP/IL-33 long-acting bispecific antibody for the treatment of chronic obstructive pulmonary disease and asthma; and QX035N, a bispecific antibody for the treatment of respiratory and dermatology diseases. Further, it manufactures and sells pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.
Key Fundamentals
P/E Ratio
10.34
Forward P/E
26.93
EPS (TTM)
HK$1.63
ROE
68.3%
Revenue Growth (YoY)
427.3%
Profit Margin
39.0%
Debt/Equity
85.41
Price/Book
4.74
Beta
1.44
Market Cap
HK$3.79B
Avg Volume (10D)
179K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
HK$22.56
60D Low
HK$14.60
Avg Volume
291K
Latest Close
HK$16.86
Get breakout alerts for 2509.HK
Sign up for Breakout Scanner to receive daily notifications when 2509.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
QYUNS-B (2509.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2509.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2509.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.